Randomized trial · people

Eloralintide: 2.6% to 11.3% weight loss at 12 weeks in phase 1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

Early human data on eloralintide show weight loss within 12 weeks of weekly dosing, with gut side effects less common than appetite loss, headache and fatigue.

Kind
Randomized trial
Studied in
People
Number studied
100
Published
2026
Journal
Diabetes Obes Metab

What they tested

The team tested whether once-weekly eloralintide shots, an amylin receptor agonist, were safe and well tolerated, how the drug behaved in the body, and what they did to body weight in people with obesity or overweight.

How the study was done

A randomized, placebo-controlled, phase 1 trial at US centers, in which 100 people with obesity or overweight (average age 44, 29% women, average BMI 32.6 kg/m2) got weekly shots under the skin of eloralintide or placebo (a dummy shot) for 12 weeks. Neither participants nor investigators knew who got which, and people were placed in 5 cohorts at rising doses, each starting on their full dose without stepping up.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking eloralintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 12, people on eloralintide lost an average of 2.6% to 11.3% of body weight depending on dose group, measured as a least squares mean (a model-adjusted average). Appetite loss was the side effect seen most often, in 19% of people on the drug; others included COVID-19 (11%), fatigue (11%) and headache (12%), and most side effects were mild. Gut problems were less frequent, with vomiting in 4%, nausea in 8% and diarrhea in 10%. Nobody died, and the single serious adverse event, in the 6 mg cohort, was judged not caused by the drug.

What it doesn’t show

This was a small, 12-week early-stage trial built mainly to check safety and drug levels, so it can't show how weight loss holds up over longer use or in a broader group. Most participants were men, and all were treated at US centers.

The paper

Bhattachar et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026.

The compound

More studies on Eloralintide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking eloralintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo